La vendita allo scoperto per Innovator ETFs Trust Innovator International Developed Power Buffer ETF November dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Innovator ETFs Trust Innovator International Developed Power Buffer ETF November. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Innovator ETFs Trust Innovator International Developed Power Buffer ETF November (ARCA:INOV), Report sulle vendite allo scoperto

Inovalon Holdings

The Fund invests at least 80 percent of its net assets in Flexible Exchange Options (FLEX Options) that reference the iShares MSCI EAFE ETF (the Underlying ETF). FLEX Options are exchange-traded option contracts with uniquely customizable terms. Although guaranteed for settlement by the Options Clearing Corporation (the OCC), FLEX Options are still subject to counterparty risk with the OCC and may be less liquid than more traditional exchange-traded option contracts. Due to the unique mechanics of the Funds strategy, the return an investor can expect to receive from an investment in the Fund has characteristics that are distinct from many other investment vehicles. It is important that an investor understands these characteristics before making an investment in the Fund.

Innovator International Developed Power Buffer ETF - November

Innovator ETFs Trust Innovator International Developed Power Buffer ETF November

INOVIO PHARMACEUTICALS ORD

INOVIQ LTD by INOVIQ LTD.

Inovalis Real Estate Investment Trust

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals Inc

Photo by<a href="https://unsplash.com/@haloirwan?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText"> Irwan iwe</a> on<a href="https://unsplash.com/s/photos/hospital-records?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText"> Unsplash</a>
The following post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga.
Technological advances have allowed us to book a trip around the world in minutes, access bank accounts, transfer funds, check investments and buy stocks with a few clicks.
But there are still several industries that could be considered behind the curve in implementing digital technology. Buying a home in many cases is a physical paperwork jungle as is the healthcare industry, which is still reliant on fax machines, paper scripts and physical file cabinets.
At least in the healthcare industry, change is coming, and several companies are looking to establish themselves as the go-to provider of the new wave of digital healthcare technology. Companies including Accolade Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/accd#NASDAQ">ACCD</a>), Inovalon Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inov#NASDAQ">INOV</a>), Health Catalyst Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcat#NASDAQ">HCAT</a>) and Phreesia Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/phr#NYSE">PHR</a>) are investing millions on emerging digital healthcare solutions that medical groups and their patients are finally embracing. It&rsquo;s a potentially lucrative <a href="https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/">sector</a>, with the healthcare cloud computing market alone expected to reach $64.7 billion by 2025.
That increased embrace is being spurred on by a global pandemic that laid bare the problems the health <a href="https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/">sector</a> has been dealing with for decades. From increased bed occupancy to overworked healthcare workers, outdated systems put healthcare systems in critical care, drastically seeking technological data transformation to rescue it.&nbsp;
Public and institutional reluctance to adopt data transformation in the heavily regulated healthcare industry is now slowly shifting. The College of Healthcare Information Management Executives (CHIME), an organization created to serve the professional development needs of chief information officers working in the healthcare industry, recently presented survey information showing that change is coming.
In the survey, more than 60% of healthcare IT executives say their organization is taking a hybrid approach to cloud operations &mdash; part cloud, part on-premise &mdash; with just under 18% saying they are not yet ready to make a move to the cloud. Nearly 10% say they are all in on the public cloud.&nbsp; Another 11% supported adopting the private cloud approach.
California-based Healthcare Triangle Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcti#NASDAQ">HCTI</a>), a provider of cloud and data transformation solutions in healthcare and life sciences, says it is jumping on the digital movement by providing expertise in digital transformation, which encompasses the cloud, security and compliance, data lifecycle management, healthcare interoperability and clinical and business performance optimization.&nbsp;
&ldquo;With the healthcare cloud computing market growing, from selecting a cloud provider to managing the cloud platform, the healthcare industry is looking to solve key challenges,&rdquo; Healthcare Triangle Vice President for Client Success, Jason Polli said. &ldquo;Capturing the expected value from the move to the cloud requires healthcare IT leaders to manage their cloud platforms differently than they would do in a data center, combining best practices in software development and IT operations. They must also staff their transition to the cloud with the right talent.&quot;
Increased use of application program interfaces (APIs) can help meet patients&rsquo; goals on their data, with doctors gaining access to more information about their medical status while only sharing data necessary for their treatment.
Healthcare Triangle believes that the healthcare industry is just starting to see the real benefits of modern APIs and translation tools bringing health data together in a typical fashion with rapid adoption and integration of advanced cloud tools and analytics. Most importantly, the company is betting on a move toward true interoperability of health data shared seamlessly between organizations, without barriers, whether technological or geographical.
To learn more about Healthcare Triangle Inc, go to <a href="http://www.healthcaretriangle.com">www.healthcaretriangle.com</a>.
The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Penny Stocks

Health Care

General

ACCD

HCAT

HCTI

INOV

Is The Digital Age Descending on a Previously Reluctant Healthcare Industry?

Inotiv, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) (the &quot;Company&quot;, &quot;We&quot;, &quot;Our&quot; or &quot;Inotiv&quot;), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the acquisition of Plato BioPharma, Inc. (&quot;PBI&quot;), a Colorado-based,&nbsp;in vivo&nbsp;pharmacology research and drug discovery company specializing in cardiovascular, renal, pulmonary and hepatic therapeutic areas. Transaction consideration totaled&nbsp;$15.0 million, consisting of:&nbsp;$10.0 million&nbsp;in cash; 57,587 Inotiv common shares having a value of&nbsp;$2.0 million&nbsp;based on the weighted average closing price of Company shares as reported by NASDAQ for the twenty trading-day period ending on September 29, 2021; and&nbsp;$3.0 million&nbsp;in unsecured promissory notes. 
&nbsp;
Inotiv expects PBI to bolster the Company&#39;s growing Boulder, Colorado, discovery operations, noting that PBI is currently expanding its facility space to accommodate approximately double their current business to support the growing demand for services.&nbsp;&nbsp;&nbsp;
&quot;The acquisition of PBI marks another milestone for Inotiv as we continue to execute on our strategy to build a complete range of contract research services that spans the entire drug discovery and preclinical development continuum,&quot; said John Sagartz, DVM, Ph.D., DACVP, Inotiv&#39;s Chief Strategy Officer. &quot;PBI&#39;s expertise and integrative approach to functional and physiological measurements, histological evaluations and biomarker analyses is complementary to our existing suite of services. This addition allows us to support and accelerate PBI&#39;s growth plans, while further expanding into more physiologic and pharmacologic offerings, enabling a wider range of clients to make informed decisions with confidence as they move toward their first-in-human clinical goals.&quot;
Craig Plato, Ph.D., Chief Executive Officer and Founder of Plato BioPharma, added, &quot;We look forward to joining the team and broadening Inotiv&#39;s service offering with our decades of pharmaceutical, biotech industry and academic research experience. Our core values and collaborative approach align well, and our focus on rigorous scientific execution and dedication to delivering exceptional client experience will continue to be paramount. With Inotiv&#39;s support, we are excited to provide our current and future clients an even more robust level of service and support to their preclinical drug discovery and development programs.&quot;
The Company expects to retain all thirty-four existing PBI employees after transaction close.
A Current Report on Form 8-K containing further details regarding the transaction will be filed by Inotiv and made available on the U.S. Securities and Exchange Commission&#39;s EDGAR website.

NOTV

Inotiv Acquires Plato BioPharma For $15M

News

Management

Inovalon Holdings Says Dunleavy Will Remain As CEO

&nbsp;
<h2>Upgrades</h2>
<ul>
<li>For Kite Realty Group Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>), Raymond James upgraded the previous rating of Outperform to Strong Buy. For the second quarter, Kite Realty Gr Trust had an EPS of $0.34, compared to year-ago quarter EPS of $0.30. The current stock performance of Kite Realty Gr Trust shows a 52-week-high of $23.14 and a 52-week-low of $10.00. Moreover, at the end of the last trading period, the closing price was at $19.13.</li>
<li>Raymond James upgraded the previous rating for Okta Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) from Outperform to Strong Buy. Okta earned $0.10 in the first quarter, compared to $0.07 in the year-ago quarter. At the moment, the stock has a 52-week-high of $294.00 and a 52-week-low of $185.05. Okta closed at $247.55 at the end of the last trading period.</li>
<li>For FactSet Research Systems Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>), Barclays upgraded the previous rating of Equal-Weight to Overweight. FactSet Research Systems earned $2.72 in the third quarter, compared to $2.86 in the year-ago quarter. At the moment, the stock has a 52-week-high of $376.57 and a 52-week-low of $294.21. FactSet Research Systems closed at $367.64 at the end of the last trading period.</li>
<li>Berenberg upgraded the previous rating for Univar Solutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNVR#NYSE">UNVR</a>) from Hold to Buy. For the second quarter, Univar Solns had an EPS of $0.57, compared to year-ago quarter EPS of $0.33. The stock has a 52-week-high of $28.00 and a 52-week-low of $15.70. At the end of the last trading period, Univar Solns closed at $23.12.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
&nbsp;
<h2>Downgrades</h2>
<ul>
<li>According to Argus Research, the prior rating for Beyond Meat Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) was changed from Buy to Hold. For the second quarter, Beyond Meat had an EPS of $0.31, compared to year-ago quarter EPS of $0.02. The stock has a 52-week-high of $221.00 and a 52-week-low of $99.86. At the end of the last trading period, Beyond Meat closed at $124.30.</li>
<li>According to JP Morgan, the prior rating for Nordstrom Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) was changed from Neutral to Underweight. Nordstrom earned $0.49 in the second quarter, compared to $1.62 in the year-ago quarter. The current stock performance of Nordstrom shows a 52-week-high of $46.45 and a 52-week-low of $11.72. Moreover, at the end of the last trading period, the closing price was at $37.81.</li>
<li>B of A Securities downgraded the previous rating for CAE Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAE#NYSE">CAE</a>) from Neutral to Underperform. CAE earned $0.15 in the first quarter, compared to $0.08 in the year-ago quarter. The current stock performance of CAE shows a 52-week-high of $32.19 and a 52-week-low of $13.80. Moreover, at the end of the last trading period, the closing price was at $28.29.</li>
<li>Cowen &amp; Co. downgraded the previous rating for Boston Beer Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) from Market Perform to Underperform. For the second quarter, Boston Beer Co had an EPS of $4.75, compared to year-ago quarter EPS of $4.88. The current stock performance of Boston Beer Co shows a 52-week-high of $1349.98 and a 52-week-low of $584.60. Moreover, at the end of the last trading period, the closing price was at $608.11.</li>
<li>According to Morgan Stanley, the prior rating for Victoria&#39;s Secret &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) was changed from Overweight to Equal-Weight. Interestingly, in the second quarter, Victoria&#39;s Secret&#39;s EPS was $1.71. At the end of the last trading period, Victoria&#39;s Secret closed at $67.39.</li>
<li>According to Morgan Stanley, the prior rating for PAE Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAE#NASDAQ">PAE</a>) was changed from Overweight to Equal-Weight. PAE earned $0.15 in the second quarter, compared to $0.17 in the year-ago quarter. The current stock performance of PAE shows a 52-week-high of $10.70 and a 52-week-low of $7.42. Moreover, at the end of the last trading period, the closing price was at $7.45.</li>
<li>According to Piper Sandler, the prior rating for Campbell Soup Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>) was changed from Overweight to Neutral. For the third quarter, Campbell Soup had an EPS of $0.57, compared to year-ago quarter EPS of $0.83. The stock has a 52-week-high of $54.08 and a 52-week-low of $41.93. At the end of the last trading period, Campbell Soup closed at $42.02.</li>
<li>For Theravance Biopharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>), Morgan Stanley downgraded the previous rating of Overweight to Underweight. For the second quarter, Theravance Biopharma had an EPS of $0.80, compared to year-ago quarter EPS of $1.00. At the moment, the stock has a 52-week-high of $22.74 and a 52-week-low of $9.20. Theravance Biopharma closed at $9.24 at the end of the last trading period.</li>
<li>According to Keybanc, the prior rating for Inovalon Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOV#NASDAQ">INOV</a>) was changed from Overweight to Sector Weight. In the second quarter, Inovalon Holdings showed an EPS of $0.19, compared to $0.15 from the year-ago quarter. At the moment, the stock has a 52-week-high of $40.52 and a 52-week-low of $17.56. Inovalon Holdings closed at $40.39 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
&nbsp;
<h2>Initiations</h2>
<ul>
<li>Deutsche Bank initiated coverage on Boohoo Group PLC (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BHHOF#OTC">BHHOF</a>) with a Buy rating. The current stock performance of Boohoo Group shows a 52-week-high of $4.65 and a 52-week-low of $3.56. Moreover, at the end of the last trading period, the closing price was at $3.80.</li>
<li>With an Outperform rating, FBN Securities initiated coverage on Tenable Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>). The price target seems to have been set at $60.00 for Tenable Holdings. Tenable Holdings earned $0.09 in the second quarter, compared to $0.04 in the year-ago quarter. At the moment, the stock has a 52-week-high of $58.45 and a 52-week-low of $33.25. Tenable Holdings closed at $42.59 at the end of the last trading period.</li>
<li>BTIG initiated coverage on Rani Therapeutics Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) with a Buy rating. The price target for Rani Therapeutics Hldgs is set to $24.00. &nbsp;Rani Therapeutics Hldgs closed at $17.76 at the end of the last trading period.</li>
<li>With a Buy rating, MKM Partners initiated coverage on Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>). The price target seems to have been set at $34.00 for Equinor. In the second quarter, Equinor showed an EPS of $0.48, compared to $0.20 from the year-ago quarter. At the moment, the stock has a 52-week-high of $23.36 and a 52-week-low of $12.11. Equinor closed at $21.04 at the end of the last trading period.</li>
<li>Cowen &amp; Co. initiated coverage on Stryve Foods Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAX#NASDAQ">SNAX</a>) with an Outperform rating. The price target for Stryve Foods is set to $12.00. Stryve Foods earned $0.26 in the second quarter. At the end of the last trading period, Stryve Foods closed at $6.74.</li>
<li>Stifel initiated coverage on Rover Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROVR#NASDAQ">ROVR</a>) with a Buy rating. The price target for Rover Group is set to $14.00. Interestingly, in the second quarter, Rover Group&#39;s EPS was $0.63. Rover Group closed at $11.29 at the end of the last trading period.</li>
<li>B of A Securities initiated coverage on Rent-A-Center Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCII#NASDAQ">RCII</a>) with a Buy rating. The price target for Rent-A-Center is set to $85.00. Rent-A-Center earned $1.63 in the second quarter, compared to $0.80 in the year-ago quarter. At the moment, the stock has a 52-week-high of $66.70 and a 52-week-low of $27.83. Rent-A-Center closed at $64.95 at the end of the last trading period.</li>
<li>With a Buy rating, Deutsche Bank initiated coverage on Ardagh Metal Packaging SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBP#NYSE">AMBP</a>). The price target seems to have been set at $14.00 for Ardagh Metal Packaging. &nbsp;Moreover, at the end of the last trading period, the closing price was at $11.67.</li>
<li>With a Buy rating, Needham initiated coverage on Alphatec Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>). The price target seems to have been set at $18.00 for Alphatec Holdings. For the second quarter, Alphatec Holdings had an EPS of $0.39, compared to year-ago quarter EPS of $0.25. At the moment, the stock has a 52-week-high of $19.36 and a 52-week-low of $5.45. Alphatec Holdings closed at $13.08 at the end of the last trading period.</li>
<li>With a Buy rating, HC Wainwright &amp; Co. initiated coverage on Salarius Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>). The price target seems to have been set at $5.00 for Salarius Pharmaceuticals. For the second quarter, Salarius Pharmaceuticals had an EPS of $0.07, compared to year-ago quarter EPS of $0.13. At the moment, the stock has a 52-week-high of $3.50 and a 52-week-low of $0.63. Salarius Pharmaceuticals closed at $0.94 at the end of the last trading period.</li>
<li>B. Riley Securities initiated coverage on Perpetua Resources Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPTA#NASDAQ">PPTA</a>) with a Buy rating. The price target for Perpetua Resources is set to $22.00. Perpetua Resources earned $0.29 in the second quarter. The current stock performance of Perpetua Resources shows a 52-week-high of $9.45 and a 52-week-low of $5.13. Moreover, at the end of the last trading period, the closing price was at $5.37.</li>
<li>With a Buy rating, Berenberg initiated coverage on Avalara Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVLR#NYSE">AVLR</a>). The price target seems to have been set at $200.00 for Avalara. For the second quarter, Avalara had an EPS of $0.02, compared to year-ago quarter EPS of $0.04. The current stock performance of Avalara shows a 52-week-high of $185.37 and a 52-week-low of $115.00. Moreover, at the end of the last trading period, the closing price was at $176.00.</li>
<li>With a Buy rating, Berenberg initiated coverage on Vertex Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>). The price target seems to have been set at $27.00 for Vertex. In the second quarter, Vertex showed an EPS of $0.08, compared to $0.16 from the year-ago quarter. The stock has a 52-week-high of $39.71 and a 52-week-low of $16.06. At the end of the last trading period, Vertex closed at $20.75.</li>
<li>B. Riley Securities initiated coverage on Vincerx Pharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) with a Buy rating. The price target for Vincerx Pharma is set to $26.00. In the second quarter, Vincerx Pharma showed an EPS of $0.12, compared to $0.01 from the year-ago quarter. The stock has a 52-week-high of $26.75 and a 52-week-low of $11.00. At the end of the last trading period, Vincerx Pharma closed at $14.47.</li>
<li>Barclays initiated coverage on Victoria&#39;s Secret &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with an Overweight rating. The price target for Victoria&#39;s Secret is set to $100.00. In the second quarter, Victoria&#39;s Secret earned $1.71. Moreover, at the end of the last trading period, the closing price was at $67.39.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Upgrades

Downgrades

Initiation

Intraday Update

Analyst Ratings

AMBP

ATEC

AVLR

BHHOF

BYND

EQNR

OKTA

PPTA

RANI

RCII

ROVR

SLRX

SNAX

TBPH

TENB

UNVR

VERX

VINC

VSCO

Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2021

Keybanc analyst Donald Hooker downgrades Inovalon Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOV#NASDAQ">INOV</a>) from Overweight to Sector Weight.

Keybanc Downgrades Inovalon Holdings to Sector Weight

&nbsp;
<h2>Upgrades</h2>
<ul>
<li>For Investors Bancorp Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISBC#NASDAQ">ISBC</a>), Stephens &amp; Co. upgraded the previous rating of Equal-Weight to Overweight. In the second quarter, Investors Bancorp showed an EPS of $0.34, compared to $0.18 from the year-ago quarter. The stock has a 52-week-high of $15.71 and a 52-week-low of $6.74. At the end of the last trading period, Investors Bancorp closed at $13.44.</li>
<li>Loop Capital upgraded the previous rating for Leslies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) from Hold to Buy. Leslies earned $0.64 in the third quarter, compared to $0.47 in the year-ago quarter. The stock has a 52-week-high of $32.84 and a 52-week-low of $19.15. At the end of the last trading period, Leslies closed at $21.60.</li>
<li>According to JP Morgan, the prior rating for Macy&#39;s Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) was changed from Underweight to Neutral. In the second quarter, Macy&#39;s showed an EPS of $1.29, compared to $0.81 from the year-ago quarter. The current stock performance of Macy&#39;s shows a 52-week-high of $22.30 and a 52-week-low of $5.57. Moreover, at the end of the last trading period, the closing price was at $21.61.</li>
<li>According to HSBC, the prior rating for CF Industries Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) was changed from Hold to Buy. CF Industries Holdings earned $1.14 in the second quarter, compared to $0.89 in the year-ago quarter. The stock has a 52-week-high of $57.19 and a 52-week-low of $25.30. At the end of the last trading period, CF Industries Holdings closed at $43.34.</li>
<li>For The Mosaic Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>), HSBC upgraded the previous rating of Hold to Buy. Mosaic earned $1.17 in the second quarter, compared to $0.11 in the year-ago quarter. The current stock performance of Mosaic shows a 52-week-high of $38.23 and a 52-week-low of $16.01. Moreover, at the end of the last trading period, the closing price was at $29.57.</li>
<li>For FibroGen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>), Raymond James upgraded the previous rating of Underperform to Market Perform. FibroGen earned $1.45 in the second quarter, compared to $0.95 in the year-ago quarter. The stock has a 52-week-high of $57.21 and a 52-week-low of $11.47. At the end of the last trading period, FibroGen closed at $11.47.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
&nbsp;
<h2>Downgrades</h2>
<ul>
<li>For Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>), Cowen &amp; Co. downgraded the previous rating of Outperform to Market Perform. Phillips 66 earned $0.74 in the second quarter, compared to $0.74 in the year-ago quarter. At the moment, the stock has a 52-week-high of $94.34 and a 52-week-low of $43.27. Phillips 66 closed at $66.27 at the end of the last trading period.</li>
<li>Argus Research downgraded the previous rating for Leidos Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) from Buy to Hold. For the second quarter, Leidos Holdings had an EPS of $1.52, compared to year-ago quarter EPS of $1.55. The current stock performance of Leidos Holdings shows a 52-week-high of $113.75 and a 52-week-low of $79.15. Moreover, at the end of the last trading period, the closing price was at $96.67.</li>
<li>BTIG downgraded the previous rating for Performance Food Group Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) from Buy to Neutral. In the fourth quarter, Performance Food Group showed an EPS of $0.56, compared to $0.86 from the year-ago quarter. At the moment, the stock has a 52-week-high of $59.89 and a 52-week-low of $31.69. Performance Food Group closed at $42.92 at the end of the last trading period.</li>
<li>RBC Capital downgraded the previous rating for Duke Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) from Outperform to Sector Perform. In the second quarter, Duke Energy showed an EPS of $1.15, compared to $1.08 from the year-ago quarter. The current stock performance of Duke Energy shows a 52-week-high of $108.38 and a 52-week-low of $78.95. Moreover, at the end of the last trading period, the closing price was at $106.88.</li>
<li>According to Raymond James, the prior rating for Healthcare Trust of America Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTA#NYSE">HTA</a>) was changed from Outperform to Market Perform. In the second quarter, Healthcare Trust showed an EPS of $0.44, compared to $0.42 from the year-ago quarter. The stock has a 52-week-high of $29.72 and a 52-week-low of $23.39. At the end of the last trading period, Healthcare Trust closed at $29.66.</li>
<li>Raymond James downgraded the previous rating for Healthcare Realty Trust Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) from Strong Buy to Market Perform. For the second quarter, Healthcare Realty Trust had an EPS of $0.43, compared to year-ago quarter EPS of $0.42. The stock has a 52-week-high of $34.01 and a 52-week-low of $26.77. At the end of the last trading period, Healthcare Realty Trust closed at $29.89.</li>
<li>For Pinnacle West Capital Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>), Goldman Sachs downgraded the previous rating of Neutral to Sell. Pinnacle West Capital earned $1.91 in the second quarter, compared to $1.71 in the year-ago quarter. At the moment, the stock has a 52-week-high of $91.88 and a 52-week-low of $69.29. Pinnacle West Capital closed at $80.08 at the end of the last trading period.</li>
<li>For Inovalon Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOV#NASDAQ">INOV</a>), BTIG downgraded the previous rating of Buy to Neutral. In the second quarter, Inovalon Holdings showed an EPS of $0.19, compared to $0.15 from the year-ago quarter. At the moment, the stock has a 52-week-high of $40.50 and a 52-week-low of $17.56. Inovalon Holdings closed at $40.32 at the end of the last trading period.</li>
<li>Cowen &amp; Co. downgraded the previous rating for Ontrak Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) from Market Perform to Underperform. For the second quarter, Ontrak had an EPS of $0.12, compared to year-ago quarter EPS of $0.37. The stock has a 52-week-high of $99.89 and a 52-week-low of $11.51. At the end of the last trading period, Ontrak closed at $11.68.</li>
<li>For Aprea Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>), JP Morgan downgraded the previous rating of Neutral to Underweight. In the second quarter, Aprea Therapeutics showed an EPS of $0.48, compared to $0.78 from the year-ago quarter. The current stock performance of Aprea Therapeutics shows a 52-week-high of $31.45 and a 52-week-low of $3.38. Moreover, at the end of the last trading period, the closing price was at $3.43.</li>
<li>Goldman Sachs downgraded the previous rating for Intercept Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICPT#NASDAQ">ICPT</a>) from Neutral to Sell. For the second quarter, Intercept Pharmaceuticals had an EPS of $0.33, compared to year-ago quarter EPS of $1.92. The current stock performance of Intercept Pharmaceuticals shows a 52-week-high of $50.75 and a 52-week-low of $13.29. Moreover, at the end of the last trading period, the closing price was at $13.84.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
&nbsp;
<h2>Initiations</h2>
<ul>
<li>Oppenheimer initiated coverage on AngioDynamics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Perform rating. In the fourth quarter, AngioDynamics showed an EPS of $0.00, compared to $0.06 from the year-ago quarter. The current stock performance of AngioDynamics shows a 52-week-high of $30.25 and a 52-week-low of $8.95. Moreover, at the end of the last trading period, the closing price was at $27.36.</li>
<li>Benchmark initiated coverage on Alterity Therapeutics Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) with a Speculative Buy rating. The price target for Alterity Therapeutics is set to $4.00. The stock has a 52-week-high of $3.58 and a 52-week-low of $1.09. At the end of the last trading period, Alterity Therapeutics closed at $1.28.</li>
<li>With a Strong Buy rating, Raymond James initiated coverage on Byrna Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>). The price target seems to have been set at $36.00 for Byrna Technologies. In the second quarter, Byrna Technologies earned $0.16. At the moment, the stock has a 52-week-high of $27.27 and a 52-week-low of $1.33. Byrna Technologies closed at $24.30 at the end of the last trading period.</li>
<li>Piper Sandler initiated coverage on OppFi Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPFI#NYSE">OPFI</a>) with a Neutral rating. The price target for OppFi is set to $7.00.&nbsp;OppFi closed at $6.21 at the end of the last trading period.</li>
<li>William Blair initiated coverage on Ryan Specialty Group Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>) with an Outperform rating. &nbsp;Ryan Specialty Group closed at $30.25 at the end of the last trading period.</li>
<li>For WSFS Financial Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSFS#NASDAQ">WSFS</a>), Seaport Global initiated coverage, by setting the current rating at Neutral. WSFS Financial earned $2.00 in the second quarter, compared to $0.46 in the year-ago quarter. At the moment, the stock has a 52-week-high of $55.18 and a 52-week-low of $24.59. WSFS Financial closed at $44.24 at the end of the last trading period.</li>
<li>HC Wainwright &amp; Co. initiated coverage on NextPlay Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTP#NASDAQ">NXTP</a>) with a Buy rating. The price target for NextPlay Technologies is set to $3.00. Interestingly, in the fourth quarter, NextPlay Technologies&#39;s EPS was $0.61. The stock has a 52-week-high of $2.39 and a 52-week-low of $1.62. At the end of the last trading period, NextPlay Technologies closed at $1.81.</li>
<li>With a Buy rating, Goldman Sachs initiated coverage on Perella Weinberg Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWP#NASDAQ">PWP</a>). The price target seems to have been set at $16.50 for Perella Weinberg Partners. Interestingly, in the second quarter, Perella Weinberg Partners&#39;s EPS was $0.32. The stock has a 52-week-high of $14.60 and a 52-week-low of $11.84. At the end of the last trading period, Perella Weinberg Partners closed at $13.29.</li>
<li>Keybanc initiated coverage on Janus International Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBI#NYSE">JBI</a>) with an Overweight rating. The price target for Janus Intl Gr is set to $18.00. In the second quarter, Janus Intl Gr showed an EPS of $0.02, compared to $0.17 from the year-ago quarter. The current stock performance of Janus Intl Gr shows a 52-week-high of $15.50 and a 52-week-low of $12.06. Moreover, at the end of the last trading period, the closing price was at $14.45.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

ANGO

APRE

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BPMP

BYRN

FGEN

ICPT

ISBC

LDOS

LESL

NXTP

OPFI

OTRK

PFGC

PowerShares Exchange Traded Fund Trust Dynamic Mid Cap Value Portfolio

RYAN

SFBS

TPLKF

WSFS

Benzinga's Top Ratings Upgrades, Downgrades For August 20, 2021

SVB Leerink analyst Stephanie Davis on thursday morning downgraded Inovalon Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOV#NASDAQ">INOV</a>) from Outperform to Market Perform and lowered&nbsp;the price target from $45 to $41.

Price Target

SVB Leerink On Thursday Morning Downgraded Inovalon Holdings to Market Perform, Lowered Price Target to $41

BTIG analyst David Larsen downgrades Inovalon Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOV#NASDAQ">INOV</a>) from Buy to Neutral.

BTIG Downgrades Inovalon Holdings to Neutral

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sonn#NASDAQ">SONN</a>) shares climbed 63.7% to close at $1.22 on Thursday after dropping 12% on Wednesday. Sonnet BioTherapeutics recently reported its financial results for the three months ended June 30th , 2021 and issued a business update.</li>
<li>Sonoma Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snoa#NASDAQ">SNOA</a>) shares gained 50.7% to settle at $8.15 in reaction to the launch of two new dental products. OroGenix Oral Hygiene Rinse is Sonoma&#39;s second dental product in the U.S. and was developed with its partner Gabriel Science LLC. Additionally, Sonoma and its partner, Medical Systems Solutions, have launched Microdacyn Oral Care for professional and consumer use in Switzerland.</li>
<li>DLocal Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dlo#NASDAQ">DLO</a>) rose 26.7% to close at $62.43 after the company reported a sharp rise in quarterly sales. The company&rsquo;s total payment volume came in at $1.5 billion, up 319% year over year.</li>
<li>Splash Beverage Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sbev#NYSE">SBEV</a>) gained 25% to settle at $2.85. Splash Beverage Group recently reported Q2 sales of $3.29 million.</li>
<li>China Liberal Education Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cleu#NASDAQ">CLEU</a>) surged 22.7% to close at $2.54.</li>
<li>Ensysce Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensc#NASDAQ">ENSC</a>) shares gained 22.4% to settle at $3.83. Ensysce Biosciences recently reported a Q2 net loss of $1 million.</li>
<li>DatChat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dats#NASDAQ">DATS</a>) rose 21.8% to close at $4.92. The company recently priced its IPO at $4.15 a share.</li>
<li>Macy&#39;s, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>) jumped 19.6% to settle at $21.61 after the company reported better-than-expected Q2 sales results. The company also raised FY21 EPS and sales guidance.</li>
<li>Krispy Kreme, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dnut#NASDAQ">DNUT</a>) gained 14.1% to settle at $14.91. Krispy Kreme recently reported second-quarter FY21 sales growth of 42.6% year-on-year, to $349.19 million.</li>
<li>Stevanato Group S.p.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stvn#NYSE">STVN</a>) surged 13.5% to close at $22.91 after the company reported Q2 EPS and sales results were higher year over year.</li>
<li>XTL Biopharmaceuticals Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xtlb#NASDAQ">XTLB</a>) gained 12% to settle at $3.9750.</li>
<li>Merus N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrus#NASDAQ">MRUS</a>) surged 11.5% to close at $22.02. The company, earlier during the month, posted a wider quarterly loss.</li>
<li>Star Equity Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/strr#NASDAQ">STRR</a>) gained 11% to settle at $2.73. The company, earlier during the month, posted a wider quarterly loss.</li>
<li>Bath &amp; Body Works, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbwi#NYSE">BBWI</a>) shares surged 10.5% to close at $65.51 after the company reported better-than-expected Q2 results.</li>
<li>AudioEye, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aeye#NASDAQ">AEYE</a>) rose 9.5% to close at $11.61. The company, last week, released Q2 results.</li>
<li>Tremor International Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trmr#NASDAQ">TRMR</a>) climbed 9.3% to close at $21.72 after reporting record results for the three and six months ended June 30, 2021.</li>
<li>Synopsys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snps#NASDAQ">SNPS</a>) gained 8.7% to settle at $315.99 after the company reported better-than-expected Q3 EPS and sales results.</li>
<li>Inovalon Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inov#NASDAQ">INOV</a>) rose 8.3% to close at $40.32 after the company agreed to be acquired by an equity consortium in an all-cash transaction with an enterprise value of approximately $7.3 billion.</li>
<li>Huaneng Power International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hnp#NYSE">HNP</a>) gained 7.4% to settle at $16.12.</li>
<li>Kohl&#39;s Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kss#NYSE">KSS</a>) jumped 7.3% to close at $55.63 after the company reported better-than-expected Q2 results and raised FY21 guidance.</li>
<li>TuSimple Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsp#NASDAQ">TSP</a>) rose 7.2% to close at $34.50.</li>
<li>GoHealth, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goco#NASDAQ">GOCO</a>) gained 5.1% to close at $4.92. Gohealth CEO Clinton Jones reported the purchase of 253,090 shares at an average price of $4.68 in Form 4 filing on Wednesday.</li>
</ul>
&nbsp;
<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>
<h3>Losers</h3>
<ul>
<li>PharmaCyte Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmcb#NASDAQ">PMCB</a>) shares dropped 64.9% to close at $3.48 on Thursday after the company announced a $70 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Ontrak, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otrk#NASDAQ">OTRK</a>) dipped 44.5% to close at $11.68. The company, earlier during the month, reported upbeat quarterly results.</li>
<li>The OLB Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/olb#NASDAQ">OLB</a>) fell 37.8% to close at $3.37 after the company reported a $6.1 million registered direct offering.</li>
<li>Rockley Photonics Holdings, Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rkly#NYSE">RKLY</a>) fell 25.9% to close at $7.41. The company recently reported Q2 results.</li>
<li>180 Life Sciences Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atnf#NASDAQ">ATNF</a>) fell 25.7% to settle at $5.11 as the company reported a $15 million private placement.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrpx#NASDAQ">VRPX</a>) shares declined 24.8% to close at $17.22. Virpax Pharmaceuticals shares jumped 49% on Wednesday on continued upward momentum after the company received an IND response from the FDA. The company said it believes the results of the response support further research on MMS019 as a treatment against SARS and influenza.</li>
<li>Grove, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grvi#NASDAQ">GRVI</a>) dropped 23.1% to settle at $5.23. Grove entered into AI industry in a strategic partnership with Alfi.</li>
<li>TScan Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcrx#NASDAQ">TCRX</a>) fell 21.2% to close at $10.62 after reporting a wider quarterly loss.</li>
<li>Flora Growth Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flgc#NASDAQ">FLGC</a>) declined 21% to close at $8.81. The company will release quarterly earnings after the closing bell today.</li>
<li>Alfi, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alf#NASDAQ">ALF</a>) fell 20.7% to settle at $8.78. Alfi and Grove announced plans to launch digital out of home campaign across 12 major markets.</li>
<li>Otonomo Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otmo#NASDAQ">OTMO</a>) dropped 18.8% to close at $6.05.</li>
<li>Impel NeuroPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/impl#NASDAQ">IMPL</a>) fell 17.4% to close at $13.22. The company recently posted a wider-than-expected quarterly loss.</li>
<li>AiHuiShou International Co. Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rere#NYSE">RERE</a>) dropped 17% to close at $8.90. Shares of Chinese companies traded lower amid further regulatory concerns in China.</li>
<li>SharpLink Gaming Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbet#NASDAQ">SBET</a>) dipped 16.8% to close at $4.50. SharpLink Gaming appointed Brian Bennett as its Chief Financial Officer, effective August 16, 2021.</li>
<li>Red Robin Gourmet Burgers, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rrgb#NASDAQ">RRGB</a>) fell 16.4% to close at $20.54 after the company reported second-quarter FY21 revenue growth of 71.9% year-on-year, to $276.98 million, missing the analyst consensus of $279.99 million.</li>
<li>CPI Card Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmts#NASDAQ">PMTS</a>) declined 16.1% to close at $22.65. The company, last week, reported higher quarterly earnings.</li>
<li>I-Mab (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imab#NASDAQ">IMAB</a>) dipped 15.8% to settle at $57.18. I-Mab, last week, announced interim data from its Phase 2/3 study evaluating plonmarlimab (TJM2 or TJ003234) for cytokine release syndrome (CRS) in patients with severe COVID-19.</li>
<li>Allied Healthcare Products, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahpi#NASDAQ">AHPI</a>) fell 15.5% to close at $9.00.</li>
<li>Sesen Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sesn#NASDAQ">SESN</a>) fell 15.3% to close at $1.11 after dropping 13% on Wednesday. The company recently received a Complete Response Letter from the FDA for bladder cancer candidate Vicineum.</li>
<li>NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) fell 15.2% to close at $11.82 as the company reported a $30 million private placement. NRx Pharmaceuticals gained around 12% on Wednesday in reaction to safety update on Zyesami (aviptadil) ACTIV-3 Critical Care Phase 3 study in COVID-19 patients.</li>
<li>Hudson Capital Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/husn#NASDAQ">HUSN</a>) shares declined 15% to settle at $2.33.</li>
<li>Gaotu Techedu Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gotu#NYSE">GOTU</a>) fell 15% to close at $2.38 after the company issued an update on regulatory development.</li>
<li>KE Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/beke#NASDAQ">BEKE</a>) fell 14.9% to close at $17.01. Goldman Sachs recently downgraded KE Holdings from Buy to Neutral and announced a $19.3 price target.</li>
<li>SGOCO Group, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgoc#NASDAQ">SGOC</a>) fell 14.3% to close at $6.17 after gaining over 67% on Wednesday.</li>
<li>UP Fintech Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tigr#NASDAQ">TIGR</a>) fell 12.9% to close at $12.92.</li>
<li>Gritstone bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grts#NASDAQ">GRTS</a>) dropped 12.4% to settle at $7.42. Gritstone bio recently entered into a funding agreement of up to $20.6 million with the Coalition for Epidemic Preparedness Innovations (CEPI).</li>
<li>VIQ Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vqs#NASDAQ">VQS</a>) fell 11.7% to close at $4.62.</li>
<li>Alcoa Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aa#NYSE">AA</a>) dipped 11% to settle at $36.92. Shares of metals and basic materials companies traded lower as macro concerns and COVID-19 uncertainty weigh on economic sentiment and cloud demand outlook.</li>
<li>Robinhood Markets, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hood#NASDAQ">HOOD</a>) fell 10.3% to close at $44.69 after the company disclosed its earnings for the first time as a public company. The company&rsquo;s total net revenues surged 131% to $565 million in the second quarter, while reporting a net loss of $502 million, versus net income of $58 million in the year-ago period. The company reported ARPU of $112, down from $115 year over year.</li>
<li>Intrepid Potash, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ipi#NYSE">IPI</a>) dropped 10.1% to close at $30.30. The company, earlier during the month, said it swung to a profit in the second quarter.</li>
<li>Membership Collective Group Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mcg#NYSE">MCG</a>) fell 9.9% to close at $10.76. Membership Collective is expected to report Q2 earnings on August 26, 2021.</li>
<li>Standard Lithium Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sli#NYSE">SLI</a>) dipped 9.2% to close at $6.50 after jumping more than 22% on Wednesday.</li>
<li>View, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/view#NASDAQ">VIEW</a>) fell 8.4% to close at $3.61. View recently announced it has postponed its Q2 earnings results amid the company&#39;s investigation concerning the adequacy of the company&#39;s previously disclosed warranty accrual.</li>
<li>Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>) fell 7.9% to settle at $470.36 after SVB Leerink downgraded the stock from Outperform to Market Perform and announced a $425 price target. The company also announced the acquisition of GRAIL, a health care company focused on life-saving early detection of multiple cancers. The company said it will hold GRAIL as a separate company during the European Commission&#39;s ongoing regulatory review.</li>
<li>Tencent Music Entertainment Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tme#NYSE">TME</a>) dropped 7.3% to close at $7.23. Needham maintained Tencent Music Enter with a Buy and lowered the price target from $25 to $18.</li>
<li>Callon Petroleum Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cpe#NYSE">CPE</a>) shares fell 6.9% to close at $25.97. Callon Petroleum, earlier during the month, announced plans to acquire the leasehold interests and related oil, gas, and infrastructure assets of Primexx Energy Partners and its affiliates.</li>
</ul>

Small Cap

Markets

Movers

Trading Ideas

AEYE

AHPI

ATNF

BBWI

BEKE

CLEU

DATS

DNUT

ENSC

FLGC

GOCO

GSX Techedu Inc. American Depositary Shares

GOTU

GRTS

GRVI

HOOD

HUSN

ILMN

IMAB

IMPL

MRUS

NRXP

OTMO

PMCB

PMTS

RERE

RKLY

RRGB

SBET

SBEV

SESN

SGOC

SNOA

SNPS

SONN

STRR

STVN

TCRX

TIGR

TRMR

VIEW

VRPX

XTLB

58 Biggest Movers From Yesterday

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sonn#NASDAQ">SONN</a>) shares jumped 141% to $1.7950 after dropping 12% on Wednesday. Sonnet BioTherapeutics recently reported its financial results for the three months ended June 30th , 2021 and issued a business update.</li>
<li>Sonoma Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snoa#NASDAQ">SNOA</a>) shares jumped 112.2% to $11.48 in reaction to the launch of two new dental products. OroGenix Oral Hygiene Rinse is Sonoma&#39;s second dental product in the U.S. and was developed with its partner Gabriel Science LLC. Additionally, Sonoma and its partner, Medical Systems Solutions, have launched Microdacyn Oral Care for professional and consumer use in Switzerland.</li>
<li>DLocal Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dlo#NASDAQ">DLO</a>) gained 37.2% to $67.61 after the company reported a sharp rise in quarterly sales. The company&rsquo;s total payment volume came in at $1.5 billion, up 319% year over year.</li>
<li>Ensysce Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensc#NASDAQ">ENSC</a>) shares jumped 25.7% to $3.9350. Ensysce Biosciences recently reported a Q2 net loss of $1 million.</li>
<li>Impel NeuroPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/impl#NASDAQ">IMPL</a>) surged 15% to $18.21. The company recently posted a wider-than-expected quarterly loss.</li>
<li>GoHealth, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goco#NASDAQ">GOCO</a>) jumped 14.3% to $5.35. Gohealth CEO Clinton Jones reported the purchase of 253,090 shares at an average price of $4.68 in Form 4 filing on Wednesday.</li>
<li>Macy&#39;s, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>) rose 14.3% to $20.72 after the company reported better-than-expected Q2 sales results. The company also raised FY21 EPS and sales guidance.</li>
<li>Vivos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vvos#NASDAQ">VVOS</a>) jumped 13.5% to $3.88.</li>
<li>TuSimple Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsp#NASDAQ">TSP</a>) rose 13% to $36.36.</li>
<li>AudioEye, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aeye#NASDAQ">AEYE</a>) gained 12.3% to $11.90. The company, last week, released Q2 results.</li>
<li>China Liberal Education Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cleu#NASDAQ">CLEU</a>) jumped 11.5% to $2.31.</li>
<li>Despegar.com, Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/desp#NYSE">DESP</a>) surged 9.7% to $12.02 following strong Q2 results.</li>
<li>Inovalon Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inov#NASDAQ">INOV</a>) gained 8.4% to $40.34 after the company agreed to be acquired by an equity consortium in an all-cash transaction with an enterprise value of approximately $7.3 billion.</li>
<li>Tremor International Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trmr#NASDAQ">TRMR</a>) rose 8.3% to $21.53 after reporting record results for the three and six months ended June 30, 2021.</li>
<li>Huaneng Power International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hnp#NYSE">HNP</a>) rose 7.6% to $16.15.</li>
<li>Kohl&#39;s Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kss#NYSE">KSS</a>) gained 7.2% to $55.59 after the company reported better-than-expected Q2 results and raised FY21 guidance.</li>
<li>Coherus BioSciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chrs#NASDAQ">CHRS</a>) rose 7.1% to $15.15. Coherus Biosciences and Shanghai Junshi Biosciences announced positive interim results from the pivotal Phase 3 clinical trial evaluating toripalimab plus</li>
<li>chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer.</li>
<li>Synopsys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snps#NASDAQ">SNPS</a>) gained 6.3% to $309.06 after the company reported better-than-expected Q3 EPS and sales results.</li>
</ul>
<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>
<h3>Losers</h3>
<ul>
<li>PharmaCyte Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmcb#NASDAQ">PMCB</a>) shares dipped 60.5% to $3.9150 after the company announced a $70 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Ontrak, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otrk#NASDAQ">OTRK</a>) fell 32.8% to $14.14. The company, earlier during the month, reported upbeat quarterly results.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrpx#NASDAQ">VRPX</a>) shares fell 31% to $15.80. Virpax Pharmaceuticals shares jumped 49% on Wednesday on continued upward momentum after the company received an IND response from the FDA. The company said it believes the results of the response support further research on MMS019 as a treatment against SARS and influenza.</li>
<li>The OLB Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/olb#NASDAQ">OLB</a>) dropped 30.4% to $3.7744 after the company reported a $6.1 million registered direct offering.</li>
<li>180 Life Sciences Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atnf#NASDAQ">ATNF</a>) declined 23.3% to $5.28 as the company reported a $15 million private placement.</li>
<li>Red Robin Gourmet Burgers, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rrgb#NASDAQ">RRGB</a>) dipped 21.8% to $19.21 after the company reported second-quarter FY21 revenue growth of 71.9% year-on-year, to $276.98 million, missing the analyst consensus of $279.99 million.</li>
<li>Flora Growth Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flgc#NASDAQ">FLGC</a>) dropped 19.7% to $8.95. The company will release quarterly earnings after the closing bell today.</li>
<li>NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) fell 19% to $11.30 as the company reported a $30 million private placement. NRx Pharmaceuticals gained around 12% on Wednesday in reaction to safety update on Zyesami (aviptadil) ACTIV-3 Critical Care Phase 3 study in COVID-19 patients.</li>
<li>SGOCO Group, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgoc#NASDAQ">SGOC</a>) fell 18.5% to $5.87 after gaining over 67% on Wednesday.</li>
<li>Grove, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grvi#NASDAQ">GRVI</a>) dropped 14.7% to $5.80. Grove entered into AI industry in a strategic partnership with Alfi.</li>
<li>KE Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/beke#NASDAQ">BEKE</a>) fell 14% to $17.19. Goldman Sachs recently downgraded KE Holdings from Buy to Neutral and announced a $19.3 price target.</li>
<li>Rockley Photonics Holdings, Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rkly#NYSE">RKLY</a>) dropped 13.7% to $8.63. The company recently reported Q2 results.</li>
<li>Sesen Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sesn#NASDAQ">SESN</a>) fell 13% to $1.14 after dropping 13% on Wednesday. The company recently received a Complete Response Letter from the FDA for bladder cancer candidate Vicineum.</li>
<li>UP Fintech Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tigr#NASDAQ">TIGR</a>) dropped 11.3% to $13.15.</li>
<li>View, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/view#NASDAQ">VIEW</a>) fell 9.6% to $3.56. View recently announced it has postponed its Q2 earnings results amid the company&#39;s investigation concerning the adequacy of the company&#39;s previously disclosed warranty accrual.</li>
<li>Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>) dropped 9.3% to $463.22 after SVB Leerink downgraded the stock from Outperform to Market Perform and announced a $425 price target. The company also announced the acquisition of GRAIL, a health care company focused on life-saving early detection of multiple cancers. The company said it will hold GRAIL as a separate company during the European Commission&#39;s ongoing regulatory review.</li>
<li>Robinhood Markets, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hood#NASDAQ">HOOD</a>) fell 9.2% to $45.22 after the company disclosed its earnings for the first time as a public company. The company&rsquo;s total net revenues surged 131% to $565 million in the second quarter, while reporting a net loss of $502 million, versus net income of $58 million in the year-ago period. The company reported ARPU of $112, down from $115 year over year.</li>
<li>Callon Petroleum Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cpe#NYSE">CPE</a>) shares fell 7.7% to $25.73. Callon Petroleum, earlier during the month, announced plans to acquire the leasehold interests and related oil, gas, and infrastructure assets of Primexx Energy Partners and its affiliates.</li>
<li>Tencent Music Entertainment Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tme#NYSE">TME</a>) dropped 7.6% to $7.21. Needham maintained Tencent Music Enter with a Buy and lowered the price target from $25 to $18.</li>
<li>Standard Lithium Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sli#NYSE">SLI</a>) fell 6.4% to $6.70 after jumping more than 22% on Wednesday.</li>
</ul>

CHRS

DESP

VVOS

38 Stocks Moving In Thursday's Mid-Day Session

WIIM

Inovalon shares are trading higher after the company announced it will be acquired by an equity consortium led by Nordic Capital, and joined by Insight Partners for $41 per share.

&nbsp;
<h1>&nbsp;</h1>
Before 10 a.m. ET on Thursday, 18 companies set new 52-week highs.
<h2>Areas of Interest:</h2>
<ul>
<li>Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) was the largest company by market cap to set a new 52-week high.</li>
<li>The smallest company when looking at market cap to set a new 52-week high was Nicholas Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICK#NASDAQ">NICK</a>).</li>
<li>DLocal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) was the biggest winner, trading up 31.32% to reach its 52-week high.</li>
</ul>
The following stocks created new 52-week highs as of 10 a.m. ET on Thursday:
<ul>
<li>Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) shares were up 0.3% on Thursday to hit a new 52-week high of $323.66 for a change of up 0.3%.</li>
<li>Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) shares achieved a new 52-week high on Thursday morning, hitting $166.50 with a daily change of up 1.2%.</li>
<li>Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) shares hit a yearly high of $310.98. The stock traded up 6.11% on the session.</li>
<li>Motorola Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) shares broke to a new 52-week high of $236.13 on Thursday. Shares of the company traded up 0.1%.</li>
<li>Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) shares set a new yearly high of $46.83 this morning. The stock was up 0.89% on the session.</li>
<li>American Water Works Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>) shares were up 0.93% on Thursday to hit a new 52-week high of $182.41 for a change of up 0.93%.</li>
<li>West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) shares set a new 52-week high of $447.11 on Thursday, moving up 0.51%.</li>
<li>Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) shares set a new 52-week high of $90.76 on Thursday, moving up 1.04%.</li>
<li>DLocal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) stock set a new 52-week high of $67.90 Thursday morning. Over the session, the stock traded up 31.32%.</li>
<li>BJ&#39;s Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) shares reached a new 52-week high of $53.88 on Thursday morning, moving up 2.16%.</li>
<li>Inovalon Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOV#NASDAQ">INOV</a>) shares hit $40.50 on Thursday morning, setting a new 52-week high for a change of up 8.8%.</li>
<li>Idacorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDA#NYSE">IDA</a>) shares were up 0.44% on Thursday morning to hit a new 52-week high of $110.21.</li>
<li>TaskUs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>) stock on Thursday broke to a yearly high of $48.50. Shares traded down 1.07%.</li>
<li>SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) stock made a new 52-week high of $121.73 Thursday. The stock was down 0.91% for the day.</li>
<li>Retail Value (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVI#NYSE">RVI</a>) shares hit a new 52-week high of $25.71. The stock traded up 0.12% on the session.</li>
<li>Eaton Vance Tax-advtgd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETO#NYSE">ETO</a>) shares hit a new 52-week high of $31.96. The stock traded up 2.24% on the session.</li>
<li>Blue Foundry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFY#NASDAQ">BLFY</a>) shares achieved a new 52-week high on Thursday morning, hitting $13.53 with a daily change of up 0.07%.</li>
<li>Nicholas Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICK#NASDAQ">NICK</a>) stock hit a yearly high price of $12.13. The stock was up 2.92% for the day.</li>
</ul>
&nbsp;
As other companies hit new 52-week lows, Benzinga will keep traders updated. Stay with us for further analysis on these and other companies.

BLFY

Eaton Vance Tax-Advantage Global Dividend Opp

NICK

SPSC

TASK

Stocks That Hit 52-Week Highs On Thursday

<ul>
<li>Provider of healthcare-focused cloud-based platforms,&nbsp;Inovalon Holdings Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inov#NASDAQ">INOV</a>) will&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/08/g22573405/inovalon-to-be-acquired-by-equity-consortium-led-by-nordic-capital-including-insight-partners-for-" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">be acquired</a>&nbsp;by an equity consortium in an all-cash transaction with an enterprise value of approximately $7.3 billion.</li>
<li>Nordic Capital and Insight Partners lead the consortium, joined by 22C Capital, Inovalon founder &amp; CEO Keith Dunleavy, and certain Class B stockholders of Inovalon.&nbsp;</li>
<li>Under the terms of the agreement, Inovalon stockholders will receive $41.00 per share.</li>
<li>The transaction is expected to close in late 2021 or early 2022.</li>
<li>Price Action:&nbsp;INOV shares gained 8.73% at $40.47 before trading halted during the market session on the last check Thursday.</li>
</ul>

Tech

Inovalon Goes Private In $7.3B Deal: See Highlights

Inovalon Holdings Shares Resume Trading

Inovalon Holdings Shares To Resume Trade At 8:30 a.m. ET

Inovalon to Be Acquired by Equity Consortium Led by Nordic Capital Including Insight Partners for $7.3B; Under The Terms Of The Agreement, Inovalon Stockholders Will Receive $41/Share In Cash

Inovalon Holdings Shares Halted, News Pending

<a href="https://www.bloomberg.com/news/articles/2021-08-19/inovalon-said-to-near-sale-to-nordic-capital-insight-partners" title="https://www.bloomberg.com/news/articles/2021-08-19/inovalon-said-to-near-sale-to-nordic-capital-insight-partners">https://www.bloomberg.com/news/articles/2021-08-19/inovalon-said-to-near-sale-to-nordic-capital-insight-partners</a>

Rumors

Inovalon Shares Hire Premarket; Bloomberg Reported Late Wednesday the Co Was Near a Sale to Nordic Capital, Insight Partners

<a href="https://pro.benzinga.com/?utm_source=insights">After pulling data from Benzinga Pro</a> it seems like during Q2, Inovalon Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOV#NASDAQ">INOV</a>) earned $24.24 million, a 3.89% increase from the preceding quarter. Inovalon Holdings also posted a total of $190.44 million in sales, a 7.49% increase since Q1. In Q1, Inovalon Holdings earned $23.33 million, and total sales reached $177.18 million. 
<h3>What Is Return On Capital Employed?</h3>
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Inovalon Holdings posted an ROCE of 0.03%.
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. 
Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders. 
For Inovalon Holdings, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies. 
<h3>Upcoming Earnings Estimate</h3>
Inovalon Holdings reported Q2 earnings per share at $0.19/share, which beat analyst predictions of $0.17/share.

Comments

Innovator ETFs Trust Innovator International Developed Power Buffer ETF November

Vendite allo scoperto

Innovator ETFs Trust Innovator International Developed Power Buffer ETF November (ARCA:INOV), Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO